Immunotherapies for Pediatric Solid Tumors: A Targeted Update.

Abstract

There are encouraging signs in our collective progress to leverage the immune system to treat pediatric cancers. Here, we summarize interim successes in cancer immunotherapy and opportunities to translate from the adult world to pediatrics, and highlight challenges that could benefit from additional development, focusing on solid tumors. Just a decade ago, other than antibodies targeting disialoganglioside (GD2) in neuroblastoma, pediatric cancer immunotherapy was mostly relegated to obscure preclinical studies in a few academic labs. Today there are numerous clinical trials of a variety of antibody, cellular, gene, and viral therapies and vaccines designed to either promote antitumor immunity or specifically attack validated immunotherapy targets. Understanding those targets and their pediatric relevance is paramount. While much work is underway to evaluate the utility of numerous immunologic targets, the lack of regulatory approvals is emblematic of the challenges that remain. Herein we focus our review on the most promising targeted immunotherapies in clinical trials for children.

• Authors: Ajay Gupta, Timothy P Cripe
• Journal: Paediatric drugs (Paediatr Drugs) Vol. 24 Issue 1 Pg. 1-12 (Jan 2022) ISSN: 1179-2019 [Electronic] Switzerland
• PMID: 34822115 (Publication Type: Journal Article)
• Copyright: © 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Chemical References

• Immunologic Factors

Topics

• Child
• Humans
• Immunologic Factors
• Immunotherapy
• Neuroblastoma